Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Simone Lisa Böll

2PUBLICATIONS

2CO-AUTHORS

Pharmaceutical delivery technologiesBiologically active molecules

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Nov 13, 2025

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review.

Simone Lisa Böll, Seyed Morteza Seyed Jafari, Curdin Conrad

|Aug 18, 2023

Rapid and sustained improvement of cutaneous lichen planus with oral JAK1 inhibitors.

Simone L Böll, Carole A Zahn, Christoph Schlapbach

Pageof 1

Frequent Collaborators

1 joint publications

Christoph Schlapbach

1 joint publications

Curdin Conrad

Frequent Collaborators

1 joint publications

Christoph Schlapbach

1 joint publications

Curdin Conrad

Top Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on : Dec 07, 2014

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on : Apr 07, 2023

See more related videos

Top Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on : Dec 07, 2014

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on : Apr 07, 2023

See more related videos